Retatrutide is Eli Lilly's next-generation weight-loss injection
Whilst the UK advises that women using GLP-1 receptor agonists should avoid pregnancy and use effective contraception, this advice is not being followed consistently in Australian clinical practice, says Associate Professor Luke Grzeskowiak
Tirzepatide is intended for adults who struggle with excess weight and related health concerns, and it is considered when traditional weight loss methods, such as diet and exercise, have not been successful
The labeling warns that concomitant use with insulin or an insulin secretagogue may increase hypoglycemia risk, including severe hypoglycemia, and separately warns about acute kidney injury due to volume depletion in patients with adverse reactions such as vomiting or diarrhea
Excited to see how much more I can achieve!" - John S
Tirzepatide administration for 72 weeks elicited significant weight reduction ranging from 5 % to 20.9 % across different trials in a dose-dependent manner